PMID- 27354904
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160629
LR  - 20200930
IS  - 2045-1253 (Print)
IS  - 2045-1261 (Electronic)
IS  - 2045-1253 (Linking)
VI  - 6
IP  - 3
DP  - 2016 Jun
TI  - Cross-sectional comparison of first-generation antipsychotic long-acting 
      injections vs risperidone long-acting injection: patient-rated attitudes, 
      satisfaction and tolerability.
PG  - 162-71
LID - 10.1177/2045125316632458 [doi]
AB  - OBJECTIVES: The objective of this study was to compare patients' attitudes and 
      satisfaction with medication and patient-rated tolerability between those 
      prescribed a first-generation antipsychotic long-acting injection (FGA-LAI) and 
      those prescribed risperidone long-acting injection (RLAI). METHOD: A 
      cross-sectional study of a representative sample of outpatients prescribed an 
      FGA-LAI or RLAI for a minimum of 6 months and attending a depot clinic. Attitudes 
      to medication were assessed by the Drug Attitude Inventory (DAI-30), tolerability 
      was measured by the Liverpool University Neuroleptic Side Effect Rating Scale 
      (LUNSERS) and satisfaction with antipsychotic medication was assessed by the 
      Satisfaction with Antipsychotic Medication (SWAM) scale. RESULTS: The RLAI (n = 
      28) and FGA-LAI (n = 39) groups did not differ in terms of mean age, sex, 
      diagnosis and ethnicity. All individual LAIs were prescribed within British 
      National Formulary limits. The most commonly prescribed FGA-LAI was flupentixol 
      decanoate (n = 22). There was no significant difference between the RLAI and 
      FGA-LAI groups in terms of mean total scores on the DAI-30, LUNSERS and SWAM or 
      the tolerability subscales of the LUNSERS or the two subscales (treatment 
      acceptability and medication insight) of the SWAM. In both LAI groups there was a 
      low level of side effects (LUNSERS) and a generally positive attitude (DAI-30) 
      and reasonable satisfaction (SWAM) with medication. CONCLUSIONS: Patients treated 
      with FGA-LAI and RLAI for at least 6 months did not differ in terms of 
      patient-rated tolerability, attitudes and satisfaction with medication. The 
      current design cannot determine whether differences would have been evident 
      earlier on during treatment. These results should be regarded as preliminary and 
      are subject to prescribing bias. Randomized studies avoid prescribing bias and 
      are a superior way to compare specific LAIs. Ideally randomized studies should 
      include patient-rated outcome measures including medication tolerability; 
      assessment of side effects, efficacy and quality of life made by blinded raters; 
      and additional objective side-effect data including changes in weight and key 
      blood parameters.
FAU - Singh, Sourabh Moti
AU  - Singh SM
AD  - Lancashire Care NHS Foundation Trust, Preston, UK.
FAU - Haddad, Peter M
AU  - Haddad PM
AD  - University of Manchester, Manchester, UK.
FAU - Husain, Nusrat
AU  - Husain N
AD  - University of Manchester, Manchester, UK.
FAU - Heaney, Eamonn
AU  - Heaney E
AD  - Lancashire Care NHS Foundation Trust, Preston, UK.
FAU - Tomenson, Barbara
AU  - Tomenson B
AD  - University of Manchester, Manchester, UK.
FAU - Chaudhry, Imran B
AU  - Chaudhry IB
AD  - Lead Consultant Psychiatrist, Lancashire Care Early Intervention Service & 
      Honorary Professor of Adult Psychiatry, University of Manchester, The Mount, 
      Whalley Road, Accrington BB5 5DE, UK.
LA  - eng
PT  - Journal Article
DEP - 20160310
PL  - England
TA  - Ther Adv Psychopharmacol
JT  - Therapeutic advances in psychopharmacology
JID - 101555693
PMC - PMC4910399
OTO - NOTNLM
OT  - depot antipsychotics
OT  - patients' attitudes
OT  - safety
OT  - satisfaction
OT  - side effects
OT  - tolerability
COIS- Conflict of interest statement: In the last 2 years PMH has received honoraria 
      for lecturing and consultancy work (including attending advisory boards) from 
      companies that market SGA-LAIs, including Janssen, Lilly, Lundbeck and Otsuka, 
      plus support to attend a conference from Janssen. IBC has received a travel grant 
      from Janssen in the last 2 years.
EDAT- 2016/06/30 06:00
MHDA- 2016/06/30 06:01
PMCR- 2016/06/01
CRDT- 2016/06/30 06:00
PHST- 2016/06/30 06:00 [entrez]
PHST- 2016/06/30 06:00 [pubmed]
PHST- 2016/06/30 06:01 [medline]
PHST- 2016/06/01 00:00 [pmc-release]
AID - 10.1177_2045125316632458 [pii]
AID - 10.1177/2045125316632458 [doi]
PST - ppublish
SO  - Ther Adv Psychopharmacol. 2016 Jun;6(3):162-71. doi: 10.1177/2045125316632458. 
      Epub 2016 Mar 10.